- Home
- HTH vs PTGX Comparison
HTH vs PTGX Comparison
Compare HTH & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | PTGX |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | 3550 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 9.3B |
| IPO Year | 2003 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HTH | PTGX |
|---|---|---|
| Price | $37.68 | $146.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $37.50 | ★ $108.23 |
| AVG Volume (30 Days) | 193.2K | ★ 454.1K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | 1.27 | ★ 2.35 |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | $3.22 | N/A |
| P/E Ratio | ★ $29.73 | $62.34 |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $30.78 | $57.45 |
| 52 Week High | $40.41 | $160.81 |
Technical Indicators
Market Signals| Indicator | HTH | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 50.11 |
| Support Level | $37.39 | $127.98 |
| Resistance Level | $38.52 | $160.81 |
| Average True Range (ATR) | 0.58 | 5.72 |
| MACD | -0.15 | -1.70 |
| Stochastic Oscillator | 4.52 | 21.62 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.